With the acquisition, AbbVie will gain ownership of Syndesis portfolio of new synaptic vesicle protein 2A (SV2A) modulators, including its lead small molecule, SDI-118. Syndesi benefits both from UCBs research expertise and from an impressive syndicate of experienced investors and their respective networks., Cognitive impairment remains an area of significant unmet need for patients not only with Alzheimers Disease but also more broadly across a range of neurological disorders, and we are excited about the potential promise of this novel therapeutic approach, says Morten Graugaard Dssing, Principal at Novo Seeds. President of Humanas primary care, Rene Buckingham, addresses the needs of many seniors facing multiple diagnoses and barriers to high-quality care. Presently in Phase Ib clinical trials, SDI-118 is being analysed for its potential ability to boost synaptic efficiency by acting on nerve terminals. Their latest funding was raised on Sep 28, 2020 from a Series A round. read more 14 Dec Synaptic dysfunction is believed to. The product, which came to AbbVie in the 2020 Allergan acquisition, is approved for a range of therapeutic indications that include treating muscle spasticity from a stroke or other injury, as well as preventing migraine headaches. When it comes to contacting clinicians and patients, the hospital switchboard can be just as [], AbbVie, alzheimer's disease, Clinical Trials, deals, life sciences M&A, neuroscience, North Chicago, UCB. Syndesi Therapeutics has raised a total of 26.2M in funding over 3 rounds. SRIW facilitates the region's economic development, contributing effectively to the modernisation, growth and restructuring of the businesses that make up the Walloon industrial network. On March 1, 2022 AbbVie (NYSE: ABBV) reported it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio (Press release, AbbVie, MAR 1, 2022, View Source [SID1234609248]). VIVES II is funded by a dozen leading Belgian and European investors such as the EUROPEAN INVESTMENT FUND (EIF), SFPI-FPIM, BNP PARIBAS FORTIS PRIVATE EQUITY BELGIUM, BPI FRANCE (France), ING BELGIUM, SOFINA, AXA BELGIUM, BELFIUS, IRD (France), NIVELINVEST, REGION BRUXELLES CAPITAL and by SOPARTEC. The biotech notes that disruption of the synaptic connectivity is found in Alzheimers and other types of dementia. According to the deal, shareholders of Syndesi will receive an upfront payment of $130m from AbbVie. . IMPROVING THE LIVES OF PATIENTS AND THEIR FAMILIES. info@prilenia.com. Syndesi's Series A financing was co-led by Novo Holdings together with Fountain Healthcare Partners, with participation from Johnson & Johnson Innovation JJDC, Inc., SRIW (Socit Rgionale d'Investissement de Wallonie), V-Bio Ventures and Vives Fund, along with UCB Ventures. AbbVies portfolio and pipeline is thin on brain drugs, particularly in the area of neurodegeneration. Fountain Healthcare Partners (www.fh-partners.com) is a life science focused venture capital fund with 176 million ($200 million) under management. Learn More. They are also entitled to get further contingent payments of up to $870m on meeting specific pre-set milestones. Syndesi Therapeutics offers modulators to improve cognition in diseases such as alzheimer's disease and other conditions causing cognitive impairment. Synaptic dysfunction is believed to underlie the cognitive impairment seen in multiple neuropsychiatric and neurodegenerative disorders. All rights reserved. WHO WE ARE . All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. Syndesi Therapeutics is developing molecules that modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Syndesi Therapeutics is developing molecules which act in a unique way on the synaptic vesicle protein SV2A. Syndesi Therapeutics is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Under the terms of the agreement, AbbVie will pay Syndesi shareholders a $130 million upfront payment with the potential for Syndesi shareholders to receive additional contingent payments of up to $870 million based on the achievement of certain predetermined milestones. addy45869 = addy45869 + 'lamerie' + '.' + 'com'; AbbVie will pay Syndesi's shareholders a $130 million upfront payment with the potential for Syndesi's shareholders to receive additional contingent payments of up to $870 million based on the achievement of certain predetermined milestones. Syndesi's unique molecules act pre-synaptically to enhance synaptic efficiency by positively modulating the function of synaptic vesicle protein 2A (SV2A), which plays a central role in regulating neurotransmission. Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic . Syndesi Therapeutics serves customers worldwide. On Mar 2, 2022 AbbVie announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. Stay up-to-date on the latest news and information from UCB, 2007 - 2022UCB S.A., Belgium. It is being evaluated in a phase 1b study to treat cognitive impairment associated with various neurodegenerative disorders such as . Dispersion and Wet Milling Technology for Pharmaceuticals, Supply Chain Support Services for Life Science Companies, Thank you for subscribing to Pharmaceutical Technology, The leading site for news and procurement in the pharmaceutical industry, Receive our newsletter - data, insights and analysis delivered to you. The VIVES Louvain Technology Fund (www.vivesfund.com) is a multi-sector technology fund which invests in the spin-offs of the Universit catholique de Louvain (UCL) and start-ups in Belgium and neighboring countries. The total value of the deal could. Le ratio de marge brute ajuste tait de 84,7 % ; la marge d'exploitation du deuxime trimestre tait de . Read more Press releases The anchor of AbbVies neuroscience portfolio is probably botox. Bone Therapeutics has a broad portfolio of innovative allogeneic cell therapy solutions across a range of indications. About UCB Ventures. Syndesi Therapeutics (www.syndesitherapeutics.com) has been established at the Centre dEntreprises et dInnovation (CEI) in Louvain-la-Neuve and will have a presence at the JLINX incubator facilities to access expertise at the Janssen campus in Beerse, Belgium. Regulating synaptic transmission represents a promising approach to treating Alzheimers Disease and other disorders with cognitive impairment. Connecting Health Systems and Life Science Researchers To Maximize the Potential of Real-world Evidence. Get the latest industry news first when you subscribe to our newsletter. Now, as part of AbbVie, the program is well positioned to move into later stages of clinical development.". Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. The acquisition further reinforces AbbVie's neurology pipeline, as four years ago, Syndesi Therapeutics gained the rights to UCB's. Latest news. About Syndesi Therapeutics Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. With AbbVies acquisition of Syndesi, we aim to advance the research of a novel, first-in-class asset for the potential treatment of cognitive impairment associated with neuropsychiatric and neurodegenerative disorders.. Syndesi Therapeutics edit_note Submit Changes Louvain-la-Neuve, Belgium http://www.syndesitherapeutics.com/ Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). according to fleur jeffries of pm live, "the acquisition further reinforces abbvie's neurology pipeline, as four years ago, syndesi therapeutics gained the rights to ucb's synaptic vesicle protein 2a (sv2a) programme, which aims to achieve synaptic efficiency, targeting the communication between neurons in the brain, which - most notably in Get the latest industry news first when you subscribe to our daily newsletter. Goodwin Procter LLP acted as lead legal counsel, along with Deloitte Legal, Belgium, and Lazard acted as the exclusive financial adviser to Syndesi. . Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. READ MORE ABOUT US. "There is a major unmet need for new therapies that can help improve cognitive function in patients suffering from difficult-to-treat neurologic diseases," saidTom Hudson, M.D., senior vice president, R&D, chief scientific officer, AbbVie. Anthos Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of genetically and pharmacologically validated innovative therapies to advance care for people living with cardiovascular and metabolic (CVM) diseases. MT-2000 is a class of agents that are designed to precisely convert pro-inflammatory M1 Macrophages to anti-inflammatory M2 macrophages. Syndesis molecule is currently in early-stage clinical development as a way to target nerve terminals to enhance synaptic efficiency. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement. Prilenia Therapeutics. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations. Therapeutic botox accounted for $2.45 billion in 2021 sales, making it the companys top neuro product. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. This press release contains forward-looking statements based on current plans, estimates and beliefs of management. The objective of the fund is to invest in the development of start-ups, from validation of the technology to commercial maturity. Alkermes Weighs Splitting Off Cancer Biz as Separate, Publicly Traded Company, The 2 Things That Made My Transition to Voice Tech Easier: A Friendly Pricing Model and Easy Implementation, Patient Files Class-action Suit Against Advocate Aurora Health Following Data Breach, Why are Healthcare Costs So High? Send. The company is rooted in the groundbreaking research of the VIB laboratory of Ludo Van Den Bosch and in the collaboration between the VIB labs of Joris de Wit and Bart De Strooper. Four years after spinning out from Belgium's UCB, Syndesi Therapeutics and its SV2A modulator programme has been bought by AbbVie for $130 million upfront. CAREERS. We are excited to see Syndesi develop our novel pro-cognitive SV2A modulators to create value for patients with cognitive impairment, said Dhavalkumar Patel, UCBs Chief Scientific Officer and Executive Vice President. See the full leadership team at Craft. - Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies, - Novel mechanism will be evaluated for the potential to mitigate synaptic dysfunction associated with cognitive deficits across a range of neuropsychiatric and neurodegenerative disorders. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding, including lysosomal storage disorders. flanders.bio wants to improve your user experience on this website. AbbVies neuroscience drug prospects are from its partnership with Calico Life Sciences, a firm founded by Google parent company Alphabet. A new whitepaper from Ventech Solutions offers helpful guidance for how to mitigate the hidden risks low-code platforms present. Back to companies T+32.2.559.9588, isabelle.ghellynck@ucb.com. COPENHAGEN, Denmark, March 1, 2022 /PRNewswire/ -- Novo Holdings, a leading international life sciences investor, today announces that its portfolio company Syndesi Therapeutics ('Syndesi'). You need JavaScript enabled to view it. Request Profile Update Download Data Home Profiles Pharmaceutical Company Europe Syndesi Therapeutics Syndesi Therapeutics Details Syndesi Therapeutics Contact Information Get News Stories Delivered to Your Inbox Your Email: Join Today About Syndesi Therapeutics. . With an upfront payment of $130 million, AbbVie gains Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. Syndesi is investigating the potential of these molecules to improve cognition in diseases such as Alzheimer's Disease and other dementias, as well as other conditions such as major depression and cognitive impairment associated with schizophrenia. About Syndesi Therapeutics Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate. The lead molecule, SDI-118, is a small molecule currently in Phase 1b studies, which is being evaluated to target nerve terminals to enhance synaptic efficiency. Lead Syndesi drug candidate SDI-118 came from UCB research of molecules that regulate SV2A, but to improve cognition rather than stop epileptic seizures. 3D Printing in Healthcare Market Size, Share, Trends Analysis Report By Region, Component (Hardware, Materials, Digital Marketing Trends in Colorectal Cancer. Syndesi, which is based in Belgium, aims to treat brain disorders by reducing the symptoms of cognitive impairment. It also presents a list of recommendations for addressing these challenges. Join our mailing list. It has been a pleasure to partner with our investors to investigate the potential of SDI-118 in early clinical studies. ABOUT HD; ABOUT ALS; NEWS. LEARN MORE There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. The lead molecule, SDI-118, was discovered by UCB before being out-licensed to Syndesi as of 2018. UCB Ventures is a 150 million strategic corporate venture fund established in 2017 to further strengthen UCB's ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases. About Syndesi Therapeutics Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Four years after spinning out from Belgium's UCB, Syndesi Therapeutics and its SV2A modulator programme has been bought. Macrophage Therapeutics has developed a proprietary targeted steroid (MT-2000 class) designed to specifically treat the disease-causing cells quarterbacking the body's inflammatory response (Macrophages). The pharmaceutical industry's most comprehensive news and information delivered every month. 2007 -2022 UCB S.A., Belgium. UCBs Neuroscience researchers in Belgium have designed a unique class of novel SV2A modulators. Innovative Med Concepts USA Private Innovative Med Concepts is a biotech company with a pipeline of novel treatments for fibromyalgia and other related . Though the deal, AbbVie will gain access to Syndesis portfolio of SV2A modulators. Novo Holdings A/S (formerly Novo A/S) is the Novo Nordisk Foundation's wholly owned holding company for Novo Nordisk A/S and Novozymes A/S.Novo Holdings A/S was established in 1999 and manages the Novo Nordisk Foundation's assets, which in 2021 was worth almost DKK 700 billion Danish Kroner (approximately US$93.73 billion) and is the largest charitable foundation in the world making Novo . Gain Therapeutics is redefining drug discovery with its SEE-Tx target identification platform. A weekly roundup of the latest news and analysis, sent every Friday. Share. UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases in immunology and neurology. The company has also benefited from support from the Walloon Region. AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio. AbbVie announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. Pipeline Prospector delivers free access to a database of Neurology drugs under clinical trials which made headlines done by Syndesi Therapeutics Novo Seeds is the early-stage investment arm of Novo Holdings (www.novoholdings.dk). Contact Information Website www.syndesitherapeutics.com MT . Fountains main office is in Dublin, Ireland, with a second office in New York. In addition to being the major shareholder in the Novo Group companies, Novo Holdings provides seed and venture capital to development-stage companies, takes significant ownership positions in well-established companies within the life sciences and manages a broad portfolio of financial assets. I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the, Precision medicine and digital health innovation for disease diagnosis, care and treatment, Enabling process intensification in biopharma manufacturing, Specialty drug launch strategy and operations, The next chapter of clinical trial services, Putting quality first in the pharma supply chain, Accelerating Biopharmaceutical Innovation, Enabling better biopharmaceutical manufacturing, Pharmaceutical Grade Silicone Manufacturer, Contract Manufacturing Service Agreements - Rising Manufacturing Opportunities Driven by Pharmaceutical Pipeline Expansion, Brain Derived Neurotrophic Factor (Abrineurin or BDNF) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, Transforming Growth Factor (TGF) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, PharmaSphere: Emerging Biotechnologies Stem Cell Therapy, Global Mergers and Acquisitions (M&A) Deals in Pharma 2021 - Thematic Research, Intrinsic Medicine enters merger with Phoenix Biotech, PTC and Blackstone enter financing partnership of up to $1bn, Pfizer records 6% decline in revenue in Q3 2022, EMA grants full marketing authorisation for AstraZenecas Covid-19 vaccine, Number of ongoing Clinical Trials (for drugs) involving Refractory Brain Metastasis by Phase, Number of ongoing Clinical Trials (for drugs) involving Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease) by Phase, Number of ongoing Clinical Trials (for drugs) involving Cerebral Infarction (Brain Infarction) by Phase, Number of ongoing Clinical Trials (for drugs) involving Brain Tumor by Phase, Number of ongoing Clinical Trials (for drugs) involving Subependymal Giant Cell Astrocytoma by Phase, Pharma: World Markets Healthcare Database, Pharma: Clinical Trial Coordinators Database, Pharma: Pipeline & Marketed Drugs Database, AbbVie exercised an exclusive option for the acquisition of TeneoOne, Chinas biopharma industry: the small molecule renaissance in rare diseases, Medical affairs in a digital-first world: Benefits and challenges. PIPELINE. Company Presentation . All rights reservedLast updated on:April, 07, 2022, Syndesi Therapeutics is based in Belgium and will leverage UCBs neurology expertise in modulating the synaptic vesicle protein SV2A. document.getElementById('cloak45869').innerHTML += '' + addy45869+'<\/a>'; and we will provide you with regular updates. "I am delighted with the closing of this deal. Clinical trial records show the drug is currently in two Phase 1b tests, one enrolling elderly patients with cognitive decline and the other testing the drug candidate in adults in remission from depression. Syndesi Therapeutics is a Pharmaceutical Company located in Belgium, Europe, and was founded in 2018. Syndesi Therapeutics is funded by 9 investors. //-->. Founded in 1973, JJDC continues a legacy of customizing deals for data-driven companies across the continuum of healthcare, with the goal of turning great ideas into transformative new pharmaceutical, medical device and consumer healthcare products. Syndesi Therapeutics is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment seen in multiple CNS disorders, including Alzheimers Disease, schizophrenia and depresson. Unlike, UCB is the world leader in SV2A research, having discovered and developed two major anti-epileptic drugs treating patients around the world. UCB identified novel modulators of SV2A that show pro-cognitive properties in preclinical models. UCB is listed on Euronext Brussels (symbol: UCB). The Company's approach is aimed at treating Alzheimer's Disease and other disorders with cognitive impairment. Registration or use of this site constitutes acceptance of our Terms of Service and Privacy Policy. //
